Please login to the form below

Not currently logged in
Email:
Password:

Akinion’s Dr Richard Jones joins Holostem Terapie Avanzate

He takes on the role of chief executive officer

Holostem Terapie Avanzate Dr Richard JonesModena, Italy-based Holostem Terapie Avanzate has appointed Dr Richard Jones as its chief executive officer.

Dr Jones moves to the cell and gene therapy specialist from Swedish biotech Akinion Pharmaceuticals, where he had served as chief executive since January last year.

He brings over two decades of industry experience to the position, including from Novartis, where he was vice president and medicines commercialisation leader for haematology and global oncology.

Prior to this, Dr Jones served as vice president, global haematology medicines leader at GlaxoSmithKline, and has also held posts at Genzyme and Shire.

Dr Paolo Chiesi, chairman of the board at Holostem, said: “On behalf of the Holostem board, I am delighted to welcome Richard to the company.

“He brings a unique combination of international and rare disease expertise, crucial for this stage of Holostem's evolution.

“We look forward to working with Richard on the continued growth of the company's development and the realisation of the potential of the technology platform.”

2nd February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics